Microglia are gatekeepers in the CNS for a wide range of pathological stimuli and they blow the whistle when things go wrong. Collectively, microglia form a CNS tissue alarm system (Kreutzberg's "sensor of pathology"), and their involvement in physiological pain is in line with this function. However, pathological neuropathic pain is characterized by microglial activation that is unwanted and considered to contribute to or even cause tactile allodynia, hyperalgesia and spontaneous pain. Such abnormal microglial behavior seems likely due to an as yet ill-understood disturbance of microglial functions unrelated to inflammation.
Introduction
Central pain can be defined as pain arising as a consequence of dysfunction of the central somatosensory system (Finnerup, 2008; Treede et al., 2008 ). This condition is highly unpleasant and does not serve a useful role, i.e. it is unwanted and pathological. In recent years, microglia have been increasingly implicated in the mechanisms underlying abnormal pain states, notably post-traumatic neuropathic pain. However, central pain can also arise from other acquired conditions such as spinal cord and brain injury, multiple sclerosis, stroke, Parkinson's disease, tumors, and epilepsy (Finnerup, 2008) . In particular, spinal cord injury frequently results in intractable chronic central pain syndromes (Knerlich-Lukoschus et al., 2008) . Activation of microglia is a feature of all these pathologies so a closer look at the microglial cell and its exact role in central pain seems justified. This article discusses how multiple microglial mechanisms including the release of signaling and effector molecules such as cytokines, chemokines and prostaglandins, microglia-synapse interactions and the endocannabinoid (eCB) pathway may contribute to central pain states. The paper further provides links to individual microglial mechanisms that are discussed in greater detail in the respective articles of this Special issue.
A rapidly growing body of evidence suggests that microglia have a causal role in the pathogenesis of persistent neuropathic pain (Inoue and Tsuda, 2009; Narita et al., 2006) . For instance, microglial NADPH oxidase 2-generated reactive oxygen species appear to be involved in the initiation of neuropathic pain in mice (Kim et al., 2010) . In line with this view, many compounds, which modify microglial functions successfully, alleviate neuropathic pain in experimental models (Toda et al., 2011) . Microglia also seem to be involved in the ethanol-induced neuropathic pain-like state in the rat (Narita et al., 2007) and could play a role in the development of pain following chronic exposure to opioids (Horvath et al., 2010; Zhou et al., 2010) . Black and Waxman discuss sodium channels and microglial function in their article of this Special issue and demonstrate that blocking sodium channels significantly attenuates several effector functions of microglia activated by exposure to ATP and LPS, supporting a role for sodium channel activity in the molecular pathways governing microglial activation. Consequently, improving our understanding of the multiple mechanisms that underlie the microglial involvement in central pain may aid the development of new and more effective pain therapeutics.
Microglia as a tissue alarm system
Activation of microglia in response to pathological stimuli is a very common phenomenon because microglial cells have a very low threshold of activation and respond to essentially all known types of CNS disease states. As a result, microglia have been termed sensors of pathology ("a sensor for pathological events in the CNS") in what has become the most highly cited publication (Web of Science) of the microglia literature (Kreutzberg, 1996) . Microglia are normal residents of brain and spinal cord parenchyma. They need to be distinguished from stromal macrophages in a perivascular location both in terms of cellular origin and function as well as from invading blood-borne cells, which can enter the CNS under certain conditions. In contrast, microglia are true parenchymal constituents and directly neighbour nerve cells as 
Microglial activation versus inflammation
The concept of microglial activation was introduced and the term ''activated microglial cells'' was coined (Graeber et al., 1988) when it became obvious that microglia are capable of up-regulating certain molecules de novo that are not normally expressed in the CNS (Graeber et al., 2011). This behavior attests to the pronounced plasticity of microglial cells, which concerns their morphology as well as their functional capabilities. M1 and M2 polarised states have also been described (Michelucci et al., 2009). Importantly, microglial activation is finely graded as well as dynamic (Graeber et al., 2011) . Thus, activated microglia may adopt different phenotypes in response to various stimuli and can become secondarily altered by for example systemic inflammation. Furthermore, their activation appears to be brain region-specific (Choi et al., 2011). These findings indicate that each case of microglial activation has to be assessed in context and that CNS autonomous and specific mechanisms of microglial activation have to be distinguished from external influences such as cytokines that may penetrate the blood-brain-barrier under conditions of systemic infection (Perry, 2010) .
Once activated microglial cells can up-regulate a number of molecules that are known to be involved in inflammatory reactions in peripheral organs. This has led to the suggestion that activated microglial cells form part of an inflammatory process in most if not all CNS pathologies. However, the overly generous application of the term "neuroinflammation" to a wide range of CNS conditions is not justified and misleading (Graeber et al., 2011). Accordingly, we do not consider central pain an inflammatory condition.
The terminological confusion surrounding microglial activation and inflammation is especially problematic in the field of pain research because there is true inflammatory pain (pain related to inflammation affecting peripheral tissues that are supplied with nociceptive fibers) while spinal microglia activation is not closely correlated with such peripheral inflammation (Lin et al., 2007 ). Yet, there may be a contributing role of spinal cord-infiltrating CD4 (+) T lymphocytes following nerve injury-induced neuropathic pain (Cao and DeLeo, 2008). Thus, clarity of the terms used to describe microglial activation is of great importance, particularly in association with pain. The neuropathological designation microgliosis refers to population changes of microglia, which occur in various disease settings but not in isolation. Microgliosis is invariably accompanied by astrogliosis but may be dominant (hence the name!). Therefore, the term microgliosis is merely descriptive and not tied to a specific pathology or molecular mechanism. Calvo and Bennett in this Special issue write on it and mechanisms of microglial changes after peripheral nerve injury.
Multiple mechanisms of microglial activation
There is a plethora of ways to get microglia excited. The relevance of this important fact for the field of pain 
Microglia are not alone
It is important to note that microglia are not the only glial cell type that has been shown to be involved in CNS pathologies associated with neuropathic pain are characterized by microglial activation that is unwanted because it contributes to or even causes central pain. However, a pathological situation does not mean that microglia automatically behave in a pathology-amplifying way. After all they are proven guardians of the brain and spinal cord and this rule applies to the vast majority of disease conditions where microglia not only clear debris or fight infections but also participate in repair processes. Yet, there are disease conditions that can affect microglia directly or indirectly (Graeber, 2010). Similarly, while microglia behave normally in physiological pain, they obviously do not do so when activated in central pain (Hulsebosch, 2008) . This is evidenced by the fact that exacerbated microglial activation is associated with the severity of neuropathic pain symptoms (Berger et al., 2011) . However, the exact nature and extent of microglial dysfunction in pathological pain remain largely unknown at present, the apparent absence of a specific pathomorphology being one characteristic and upregulation of microglial purinergic receptors another (see article by Inoue and Tsuda, this issue). Furthermore, a theory of glia-driven mood and cognitive dysfunction in chronic pain has been proposed (Panigada and Gosselin, 2011).
In order to understand abnormal microglial behavior better it may be helpful to look at other dysfunctional states where microglia seem involved and which also lack overt microglial pathology but to look in greater detail including at their ultrastructure and relationship to synapses (Tremblay et al., 2010). In addition, although our understanding of microglial activation is incomplete and only a few regulatory mechanisms are known at present, it seems advisable to assess each case of microglial activation in context. Therefore, CNS autonomous specific microglial activation needs to be distinguished from potentially confounding processes, which extend beyond the nervous system such as systemic infection and which can influence the activation state of microglial cells within the CNS. 
Conclusions and outlook
Resistance to morphine (Mika, 2008) characterizes neuropathic pain. Therefore, elucidation of the mechanisms underlying opioid receptor control by microglia seems important. Moreover, there is an obvious need for ultrastructural studies of microglia-synapse interactions in pain states. This seems important because it has been suggested that the mechanisms that produce neuropathic pain after exposure to chemotherapeutics may be fundamentally different from those operating after nerve trauma 
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